Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Proacta Incorporated
The US FDA has given Proacta the go-ahead to begin clinical trials of PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer.
Sleep apnea is now widely recognized as an underlying factor for major CV diseases and metabolic disorders, making it a huge market opportunity. ApniCure hopes that by avoiding the CPAP masks that patients hate while using the differential pressure therapy that doctors and payors like, it can unlock this potential blockbuster market.
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.